Pfizer/Bristol finalize metabolics development deal
Executive Summary
Pfizer and Bristol-Myers Squibb finalize agreement to research, develop and commercialize DGAT-1 inhibitors. Companies announced deal to collaborate on the DGAT-1 discovery program, which includes advanced pre-clinical compounds with potential applications for treatment of metabolic disorders like obesity and diabetes, in April (1"The Pink Sheet" April 30, 2007, p. 4). Pfizer will be responsible for all research and early-stage development, and the companies will jointly conduct Phase III development and commercialization. The two firms also have a separate deal to develop and market the Factor Xa inhibitor apixaban. Initial filing for apixaban, for venous thromboembolism, is expected in the second half of 2009...
You may also be interested in...
Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget
Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.